Evidence map›Paper›PMID 41324740›Full record

ArticleMolecular biology reports2025

Circulating MiRNAs in thyroid cancer: prognostic promise of miR-155 and limitations of miR-429.

Doha R Ibrahim, Safinaz H El-Kholany, Maivel H Ghattas, Mamdouh El-Nahas, Noha M Abd El-Fadeal

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Doha R IbrahimMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Port Said University, Port Said, 42526, Egypt. doharaafat@med.psu.edu.eg.ORCID https://orcid.org/0009-0002-7737-795X
Safinaz H El-KholanyMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Port Said University, Port Said, 42526, Egypt.ORCID https://orcid.org/0009-0003-7713-5421
Maivel H GhattasMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Port Said University, Port Said, 42526, Egypt.ORCID http://orcid.org/0000-0002-1693-2932
Mamdouh El-NahasEndocrinology Department, Faculty of Medicine, Port Said University, Port Said, 42526, Egypt.ORCID http://orcid.org/0000-0001-8322-2829
Noha M Abd El-FadealMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia, 41522, Egypt. noha_abdelfadeal@med.suez.edu.eg.ORCID http://orcid.org/0000-0003-1852-4374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid cancer is now the most commonly diagnosed endocrine malignancy over the past decade, with its incidence having risen sharply. Due to its asymptomatic presentation and poor prognosis when detected at advanced stages, early diagnosis of papillary thyroid cancer (PTC) remains a challenge, even with recent medical advancements. Fortunately, serum-based miRNA testing offers a safe, minimally invasive, and repeatable diagnostic tool. Among promising miRNAs, miRNA-155 has emerged as a potential biomarker for diagnosis and prognosis and, miRNA-429 appears to be more variable and cancer-type specific.

objectiveThis study aimed to assess the expression levels of miRNA-155 and miRNA-429 and to evaluate their correlation with patient prognosis in thyroid cancer. SUBJECTS AND

methodsThe study cohort comprised 37 patients with benign thyroid tumors, 37 patients with thyroid cancer, and 74 healthy, age- and sex-matched controls. Plasma samples were collected from all participants, and the expression levels of miRNA-155 and miRNA-429 were quantified using quantitative real-time polymerase chain reaction (qPCR).

resultsmiR-155 expression was significantly upregulated in both benign and malignant thyroid tumors compared to controls (p < 0.001), whereas miR-429 expression was markedly downregulated in both tumor groups relative to controls (p < 0.001). Additionally, miR-155 expression shows weak positive correlation with lymph node involvement in patients with thyroid cancer.

conclusionmiR-155 appears to be a promising minimally invasive biomarker for thyroid malignancy, while miR-429 cannot reliably distinguish malignant from non-malignant lesions; further studies are needed to validate these findings.

Indexed as

Circulating MicroRNAMicroRNAsThyroid NeoplasmsAdultBiomarkers, TumorCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorCirculating MicroRNAMicroRNAsMIRN155 microRNA, humanMIRN429 microRNA, humanMiRNAMiRNA − 155MiRNA- 429PrognosisThyroid cancer

Identifiers

PMID41324740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.